CellaVision strengthens its product portfolio with two new products
ET | Source:CellaVision
This information was released for public disclosure on 2014-04-16 at 13.00 pm.
CellaVision announced today the launch of two new products. CellaVision® DM9600,
a replacement for CellaVision®DM96 for use in large laboratories, and
CellaVision® Advanced RBC Application, a unique software application for
advanced analysis of red blood cells.
The target market for CellaVision DM9600 and CellaVision Advanced RBC
Application is clinical laboratories that handle large testing volumes and
require a large capacity. With these products, CellaVision continues to lead the
way in their field of technology, and further strengthen its position in the
global market for hematology.
"The development of a replacement for our most successful analyzer, the
CellaVision DM96, has been finalized and we are proud to introduce a new
instrument that is based on the same patented hardware platform as our other two
analyzers". The CellaVision Advanced RBC Application offers future and existing
customers unique opportunities to assess red blood cells based on shape, size
and color, an important analysis for anemia and other disorders "says Yvonne
Mårtensson, CEO of CellaVision.
On July 1 the CellaVision DM9600 becomes commercially available in both Europe
and the U.S., with the CellaVision Advanced RBC Application initially available
in Europe only. Both products will be sold by the company's global distributor
network. CellaVision will apply for the necessary approvals to sell it in other
markets. The official market introduction will take place at the ISLH Congress
in The Hague, Netherlands, on 15-17 May 2014. Customers can rely on continued
provision of service and support for the discontinued CellaVision DM96 analyzer
according to CellaVision's End-of-Life Policy.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 0708 33 77 82 | E-mail: email@example.com
CellaVision - leading the way in digital cell morphology
CellaVision is an innovative, global medical technology company that develops
and sells its own leading product concept for routine analysis of blood and
other body fluids in health care services. The concept rationalizes manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. CellaVision's product portfolio
consists of analyzers, applications, software, and consumables. In 2013 sales
were SEK 180 million and sales continue to increase, with a growth target of at
least 15 % per year over an economic cycle. CellaVision's registered office is
in Lund and the company has subsidiaries in the USA, Canada and Japan. The share
is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at
The information in this interim report is disclosed by CellaVision AB (publ)
pursuant to the Securities Market Act and/or the Financial Instruments Trading
Act. The information was released for public disclosure on 2014-04-16 at 13.00
GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.